AMBER BABB: Open Payments
NPI 1316788060 · BRANSON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$279 in 15 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $279
Food & beverage: $279
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 5 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Novo Nordisk Inc | 1 | $26 |
| Dexcom, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $20 |
| Viatris Specialty LLC | 1 | $18 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
| Exact Sciences Corporation | 1 | $15 |
Products named: KISUNLA, CAPLYTA, FANAPT, Rybelsus, Dexcom G6 Transmitter, REXULTI, YUPELRI, MOUNJARO.
Industry payments across MO — which companies pay providers there.
